Effect of saroglitazar on glycaemic parameters: A systematic review and meta‐analysis of randomized controlled trials
Authors' conclusion
Our results revealed that saroglitazar therapy improves glycaemic parameters through the reduction of fasting glucose, postprandial glucose and HbA1c.
Study context
- Population
- Patients with dyslipidaemia, T2D and NAFLD; mean age 49.7 years, 40% female
- Participants
- 2,077 patients10 clinical trials
- Comparison
- Saroglitazar vs active control or placebo
- Outcome
- Changes in glycaemic parameters
Methodological detailsrandom-effects model, generic inverse variance method, leave-one-out sensitivity analysis, Cochrane risk-of-bias tool version 2, Risk of bias: 2 trials low, 7 some concerns, 1 high
- Random-effects model
- Generic inverse variance method
- Leave-one-out sensitivity analysis
- Cochrane risk-of-bias tool version 2
- Risk of bias: 2 trials low, 7 some concerns, 1 high
Pooled result
As reported in the abstract
Fasting glucose, postprandial glucose and HbA1c
Saroglitazar vs Active control or placeboWMD, mg/dL (95% CI)P value
Fasting glucose; I2 = 40%
−12.11(−14.79 to −9.43)
P < 0.0001Postprandial glucose; I2 = 0%
−16.17(−22.29 to −10.04)
P < 0.0001Saroglitazar vs Active control or placeboWMD, % (95% CI)P value
HbA1c; I2 = 72%
−0.39(−0.57 to −0.22)
P < 0.0001Further pooled results
| Outcome | WMD (μU/mL) (95% CI) | P value | |
|---|---|---|---|
| Insulin levelsI2 = 37%; no significant effect | −1.03 (−4.12 to 2.06) | P = 0.51 | |
| −6−4−2024Difference, μU/mL (linear scale) |
| Outcome | WMD (95% CI) | P value | |
|---|---|---|---|
| HOMA-IRI2 = 41%; no significant effect | −0.41 (−0.86 to 0.04) | P = 0.07 | |
| −1−0.500.5Difference (linear scale) |
| Outcome | WMD (ng/mL) (95% CI) | P value | |
|---|---|---|---|
| C-peptideI2 = 0%; no significant effect | −0.30 (−0.76 to 0.15) | P = 0.19 | |
| −1−0.500.5Difference, ng/mL (linear scale) |
Original publication
Effect of saroglitazar on glycaemic parameters: A systematic review and meta‐analysis of randomized controlled trials. Diabetes Obes Metab. Published 16 June 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →